Front Row Advisors’s BioTelemetry, Inc. BEAT Stock Holding History

Front Row Advisors’s Portfolio BEAT Stock Details BEAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-28,654	Closed	-$2.06M	–	985
2020 Q4	$2.06M	Sell	28,654 -165	-0.6%	-$8.64K	1.06%	27
2020 Q3	$1.55M	Sell	28,819 -590	-2%	-$24.7K	0.82%	40
2020 Q2	$1.33M	Sell	29,409 -380	-1%	-$17K	0.82%	38
2020 Q1	$1.39M	Buy	29,789 +695	+2%	+$32K	0.94%	34
2019 Q4	$1.35M	Buy	29,094 +2,840	+11%	+$123K	0.88%	40
2019 Q3	$1.07M	Buy	26,254 +1,165	+5%	+$50.3K	0.76%	48
2019 Q2	$1.21M	Buy	+25,089	New	+$1.32M	0.88%	43

Other funds holding BEAT

LCM

Logan Capital Management Newtown Square, Pennsylvania $2.3B AUM 30.85% 1-Year Est. Return

Front Row Advisors's BEAT Position: Q1 2021 in Review

Front Row Advisors sold out of BioTelemetry, Inc. (BEAT) in Q1 2021, closing a stake of 28,654 shares — an estimated $2.06M sold.

Front Row Advisors first reported a position in BEAT in Q2 2019 and held it in 7 quarters. The position peaked at $2.06M in Q4 2020. 1 fund tracked by Wall St. Rank holds BEAT as of Q1 2021.

Front Row Advisors reported no remaining BioTelemetry, Inc. position as of Q1 2021 after selling out during the quarter.
Front Row Advisors sold 28,654 BioTelemetry, Inc. shares in Q1 2021, an estimated $2.06M.
Front Row Advisors first reported a position in BioTelemetry, Inc. in Q2 2019 and held it in 7 quarters.
Front Row Advisors's BioTelemetry, Inc. position peaked at $2.06M in Q4 2020.
1 fund tracked by Wall St. Rank held BioTelemetry, Inc. as of Q1 2021.

Based on Front Row Advisors's 13F filing for Q1 2021, filed 28 Apr 2021.